Sign In
Buy PEPG
$1.42
-0.0300 (-2.07%)
At Close: Jun 03, 2026
PEPG Investors Eligible To Participate In The PepGen Inc Securities Fraud Investigation With The Schall Law Firm
09:45pm, Thursday, 08'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("Pe
Lost Money on PepGen Inc. (PEPG)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
10:30am, Thursday, 08'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federa
PepGen Inc. (PEPG) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
12:15pm, Friday, 02'nd Aug 2024
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federa
Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG)
10:35am, Friday, 02'nd Aug 2024
The heavy selling pressure might have exhausted for PepGen (PEPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Inve
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
10:00am, Thursday, 01'st Aug 2024
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Inve
PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments
02:01pm, Wednesday, 31'st Jul 2024
PepGen Inc. achieved positive data from the phase 2 CONNECT1 study, using PGN-EDO51 for the treatment of exon 51 skipping DMD patients; higher 10 mg/kg dosing of drug data is expected in early 2025. T
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se
Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why
09:52am, Wednesday, 17'th Jul 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, PepGen (PEPG) could be a great choice. It is one of the several stocks that passed through our "Recent Price St
PepGen Announces Executive Team Promotions
07:00am, Tuesday, 11'th Jun 2024
BOSTON--(BUSINESS WIRE)--This is an appointment release for PepGen. They are announcing 2 promotions on their team.
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
04:02pm, Tuesday, 14'th May 2024
– CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – – N et
Best Momentum Stocks to Buy for April 25th
11:00am, Thursday, 25'th Apr 2024
TXO, PEPG and ERO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 25, 2024.
New Strong Buy Stocks for April 25th
07:56am, Thursday, 25'th Apr 2024
TAK, TXO, PEPG, ERO and RMNI have been added to the Zacks Rank #1 (Strong Buy) List on April 25, 2024.
PepGen to Participate in Upcoming Investor Conferences
04:05pm, Wednesday, 13'th Mar 2024
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
07:00am, Wednesday, 13'th Mar 2024
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t
